NEW YORK (GenomeWeb) – RainDance Technologies has appointed Martin Coyne II and Glenn Muir to its board of directors.
Coyne retired from Eastman Kodak in July 2003. He had served there as president of health imaging, president of the commercial business group, and most recently as executive VP of Eastman Kodak and group executive of the photography group. He is chairman of the board of RockTech, a privately held SaaS business, and sits on the board of Akamai.
Muir most recently served as CFO of Hologic, a position he held from 1992 to May 2014. He also was on Hologic's board of directors. Muir also is the audit committee chair at ReWalk Robotics.
Don Lindberg, who has been the director of the National Library of Medicine for more than 30 years, will retire at the end of March 2015, NIH Director Francis Collins said this week. Lindberg created the National Center for Biomedical Information, and he introduced numerous projects including free Internet access to MEDLINE via PubMed, MedlinePlus for the general public, the Visible Human Project, ClinicalTrials.gov, the Unified Medical Language System, and more, Collins said.
Lindberg also was founding director of the National Coordination Office for High Performance Computing and Communications in the President's Office of Science and Technology Policy and was named by the HHS Secretary to be the US National Coordinator for the G-7 Global Healthcare Applications Project. In addition, he was the first president of the American Medical Informatics Association.
"Don has created programs that changed fundamentally the way biomedical information is collected, shared, and analyzed," Collins said in a statement.
Horizon Discovery Group appointed David Smoller as an executive director. Smoller joined Horizon as chief business officer as a result of its acquisition of Sage Labs, where Smoller was the CEO. Previously, he was CSO of Sigma-Aldrich and president of its research biotechnology business unit. Before joining Sigma-Aldrich, he was president of ProteoPlex, a seed stage spinout focused on proteomics and founded Genome Systems.
GeneSegues Therapeutics has named Laura Brod as its new CEO.
Brod is currently an at-large member of the University of Minnesota Board of Regents. She was previously a member of the Minnesota House of Representatives.
Human Longevity has hired Barry Merriman as vice president of global technology assessment and Paul Mola as head of global solutions. The two will work together in Human Longevity's new Global Solutions Initiative to seek business opportunities worldwide.
Merriman was previously lead system architect for advanced DNA sequencing at Life Technologies (now a division of Thermo Fisher Scientific). He was also formerly co-founder and CSO of Life Tech's Enterprise Genomics Solutions Group, and was on the faculty of the University of California, Los Angeles.
Mola also joins Human Longevity from Life Tech, where he was head of strategy and chief of staff for the genetic systems division and also a co-founder of the Enterprise Genomics Solutions Group. He also held product development roles at Applied Biosystems and Roche Diagnostics.
Transgenomic said this week that Mark Colonnese has resigned as CFO and executive vice president, effective Oct. 30, 2014. Transgenomics President and CEO Paul Kinnon will assume the role of interim CFO.
Additionally, Leon Richards, Transgenomic's corporate controller, will take on additional responsibilities as chief accounting officer. Richards joined the financial group at Transgenomic in 2012. Previously, he served as corporate controller and chief accounting officer at Baldwin Technology Company. Earlier in his career he was director of financial reporting and control at Ciba Specialty Chemicals (now BASF), and he also held positions of increasing responsibility in the financial group at Hercules (now Ashland Chemical).
Molecular diagnostics firm Great Basin Scientific has appointed Jeffrey Rona as CFO. His appointment went into effect on Oct. 8 in conjunction with the company's initial public offering.
Rona has served as a financial consultant to Great Basin since 2012 in his role as the managing director of Rona Capital, a life sciences-focused transactional advisory consultancy founded in 2011. From 2006 to 2011, Rona was the chief business officer of GlobeImmune. Prior to that, he was vice president of corporate development for Corgentech, following the merger between Corgentech and AlgoRx Pharmaceuticals in 2005. At AlgoRx, he was CFO and responsible for the execution of the merger with Corgentech. Rona has also worked for UBS Warburg, Antigenics (now Agenus), and Coopers and Lybrand.
Pathway Genomics has appointed Glenn Braunstein to its medical advisory board. He is currently the vice president of clinical innovation, director of the Thyroid Cancer Center, and professor of medicine at Cedars-Sinai. He also has served for 26 years as chair of the department of medicine at Cedars-Sinai.
Premaitha Health as appointed Yves Derveaux as regional European sales consultant for Southern Europe as the company prepares to launch its non-invasive prenatal test, Iona. Before joining Premaitha Health, Derveaux was country manager of France and sales of Southern Europe for Epigenomics and country manager of France and Switzerland at Agendia. Derveaux will report to Premaitha Health COO Peter Collins.
Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.